Overview
Nicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/08/23 | Phase 2 | Not yet recruiting | |||
2024/08/02 | Phase 1 | Active, not recruiting | |||
2024/03/22 | Not Applicable | Not yet recruiting | |||
2022/08/02 | Phase 4 | Recruiting | |||
2021/03/26 | Phase 2 | Completed | |||
2021/03/22 | Phase 4 | Completed | |||
2020/08/27 | Early Phase 1 | Active, not recruiting | |||
2020/06/12 | Early Phase 1 | Recruiting | |||
2019/10/02 | Phase 2 | Active, not recruiting | Donna Hammond, PhD | ||
2019/10/01 | Phase 1 | Completed | Oslo University Hospital |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| NAD+NMN Plus | 373212 | Aus Nature Pharmaceuticals Pty Ltd | Medicine | A | 8/20/2021 |
Help Us Improve
Your feedback helps us provide better drug information and insights.